AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35325020 — intervention group
Group type: EXPERIMENTAL
Intervention: BABEL approach to advance care planning (structured discussion of ~60 minutes)
Number of subjects: 713
Study 35325020 — intervention group
Group type: COMPARATOR
Intervention: Usual advance care planning processes in control NHs
Number of subjects: 713
Study 36066851 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib plus Olaparib
Number of subjects: 0
Study 36066851 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy
Number of subjects: 0
Study 33793110 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (tamsulosin hydrochloride 0.2 mg nightly)
Number of subjects: 70
Study 33793110 — intervention group
Group type: COMPARATOR
Intervention: Medication (tamsulosin hydrochloride 0.2 mg nightly)
Number of subjects: 70
Study 34739450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg/hour)
Number of subjects: 90
Study 34739450 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg/hour)
Number of subjects: 90
Study 34739450 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 90
Study 34739450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90
Study 34739450 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 34739450 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 33743263 — intervention group
Group type: EXPERIMENTAL
Intervention: MONO-TM
Number of subjects: 50
Study 33743263 — intervention group
Group type: COMPARATOR
Intervention: MODULAR-FM
Number of subjects: 50
Study 35074451 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 80
Study 35074451 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 80
Study 33221299 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (DCB)
Number of subjects: 40
Study 33221299 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 40
Study 33252241 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine-Assisted Activity (EAA) program, 40 minutes twice a week for 16 weeks (32 sessions)
Number of subjects: 26
Study 33252241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 26
Study 32330694 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD)
Number of subjects: 38
Study 32330694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 38
Study 35220449 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 758
Study 35220449 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent (DES)
Number of subjects: 758
Study 34564020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (150 mg twice daily)
Number of subjects: 108
Study 34564020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 34564020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 108
Study 34409915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG (2940 nm) laser
Number of subjects: 20
Study 34409915 — intervention group
Group type: COMPARATOR
Intervention: Long pulsed Nd:YAG (1064 nm) laser
Number of subjects: 20
Study 36468605 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual caregiver yoga (CY)
Number of subjects: 67
Study 36468605 — intervention group
Group type: COMPARATOR
Intervention: Dyadic yoga (DY)
Number of subjects: 67
Study 33740344 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal (TF) cervical epidural steroid injection
Number of subjects: 80
Study 33740344 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasagittal interlaminar (IL) cervical epidural steroid injection
Number of subjects: 80
Study 32379118 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulating spacer
Number of subjects: 68
Study 32379118 — intervention group
Group type: COMPARATOR
Intervention: Static spacer
Number of subjects: 68
Study 36226676 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min massage doses
Number of subjects: 273
Study 36226676 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min massage doses
Number of subjects: 273
Study 36226676 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min massage doses
Number of subjects: 273
Study 36226676 — intervention group
Group type: EXPERIMENTAL
Intervention: 3×/week massage doses
Number of subjects: 273
Study 36226676 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min doses
Number of subjects: 273
Study 33570485 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM)
Number of subjects: 49
Study 33570485 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM)
Number of subjects: 49
Study 33570485 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM MIC
Number of subjects: 49
Study 33570485 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological changes
Number of subjects: 49
Study 34237699 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH
Number of subjects: 1862
Study 34237699 — intervention group
Group type: EXPERIMENTAL
Intervention: HEI‐2015
Number of subjects: 1862
Study 34237699 — intervention group
Group type: EXPERIMENTAL
Intervention: MD
Number of subjects: 1862
Study 34237699 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐DII
Number of subjects: 1862
Study 32067724 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmically enhanced music
Number of subjects: 25
Study 32067724 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 25
Study 34491142 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenotomy for PTT (surgical treatment arm, n = 24)
Number of subjects: 47
Study 34491142 — intervention group
Group type: COMPARATOR
Intervention: Observational/control arm (n = 23)
Number of subjects: 47
Study 34453688 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (1.5 mA, 20 min)
Number of subjects: 21
Study 34453688 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 21
Study 34053119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin patch
Number of subjects: 100
Study 34053119 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron
Number of subjects: 100
Study 32767766 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium for oral solution (50 mg)
Number of subjects: 25
Study 35185013 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-strain (TS) probiotic
Number of subjects: 173
Study 35185013 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-strain (SS) probiotic
Number of subjects: 173
Study 35185013 — intervention group
Group type: COMPARATOR
Intervention: Probiotic supplementation (PS)
Number of subjects: 173
Study 33143164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed + cisplatin (PEM)
Number of subjects: 548
Study 33143164 — intervention group
Group type: COMPARATOR
Intervention: Etoposide + cisplatin (ETO)
Number of subjects: 548
Study 33657762 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic acupoint dry cupping therapy plus lifestyle modifications for 8 weeks
Number of subjects: 30
Study 33657762 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modifications for 8 weeks
Number of subjects: 30
Study 32489807 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early PCI (within 3-12 hours)
Number of subjects: 420
Study 32489807 — intervention group
Group type: COMPARATOR
Intervention: Early PCI (within 12-24 hours)
Number of subjects: 420
Study 33507394 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated Dentin Matrix Hydrogel (TDMH)
Number of subjects: 45
Study 33507394 — intervention group
Group type: COMPARATOR
Intervention: Biodentine
Number of subjects: 45
Study 33507394 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 45
Study 33032710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 336
Study 33032710 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 336
Study 35620204 — intervention group
Group type: EXPERIMENTAL
Intervention: AI technology combined with ultrasound-guided needle knife interventional therapy
Number of subjects: 130
Study 34242445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow
Number of subjects: 16
Study 34242445 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile flow
Number of subjects: 16
Study 34242445 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pulsatility
Number of subjects: 16
Study 32200533 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 at 2g (QD) for 8 weeks
Number of subjects: 37
Study 32200533 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 at 4g (2g BID) for 8 weeks
Number of subjects: 37
Study 36215289 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus pemetrexed-based chemotherapy
Number of subjects: 8
Study 36215289 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 8
Study 33108484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration peptide-HAP suspension (0.5 wt% HAP; Curodont, Credentis)
Number of subjects: 40
Study 33108484 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration peptide-HAP suspension (6.25% HAP; Curodont Protect)
Number of subjects: 40
Study 33108484 — intervention group
Group type: COMPARATOR
Intervention: Commercial bleaching agent (VivaStyle Paint on Plus, VS, Ivoclar Vivadent)
Number of subjects: 40
Study 32597706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 0
Study 32597706 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 33731570 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (1:2.5, 1:5, 1:7.5)
Number of subjects: 15
Study 33731570 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 15
Study 32753571 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-layer barbed suture (group A)
Number of subjects: 582
Study 32753571 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suturing of the joint capsule (group B)
Number of subjects: 582
Study 32753571 — intervention group
Group type: COMPARATOR
Intervention: Traditional absorbable suture (group C)
Number of subjects: 582
Study 33969750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 968
Study 33969750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 34167324 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRINT trial
Number of subjects: 3048
Study 34167324 — intervention group
Group type: EXPERIMENTAL
Intervention: RESTORE trial
Number of subjects: 3048
Study 32289474 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 day hypofractionated PMRT regimen (3.33 Gy daily to the chest wall and regional lymphatics in 11 fractions, with optional 4 fraction mastectomy scar boost)
Number of subjects: 67
Study 32289474 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 day hypofractionated PMRT regimen
Number of subjects: 67
Study 35502503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume TFEB with steroids (group D)
Number of subjects: 54
Study 35502503 — intervention group
Group type: COMPARATOR
Intervention: High-volume TFEB without steroids (group L)
Number of subjects: 54
Study 34535170 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) training and mentorship
Number of subjects: 209
Study 34535170 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) support
Number of subjects: 209
Study 36109422 — intervention group
Group type: EXPERIMENTAL
Intervention: Osc+ condition (increased heart rate oscillations)
Number of subjects: 106
Study 36109422 — intervention group
Group type: COMPARATOR
Intervention: Osc- condition (little effect on heart rate oscillations)
Number of subjects: 106
Study 34385097 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile app
Number of subjects: 40
Study 32306987 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance targeted therapy after chemotherapy
Number of subjects: 0
Study 32306987 — intervention group
Group type: EXPERIMENTAL
Intervention: Agents with a positive efficacy signal
Number of subjects: 0
Study 35307550 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg CBD
Number of subjects: 12
Study 35307550 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg CBD
Number of subjects: 12
Study 33617635 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 25
Study 33617635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 35938351 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic diet (Synbio® blend)
Number of subjects: 97
Study 35938351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 35079596 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation + CogRx
Number of subjects: 150
Study 35079596 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation only
Number of subjects: 150
Study 35079596 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 150
Study 32106174 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 20
Study 35609202 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning intervention (FP) including up to six counseling sessions, free transportation to FP clinic, free FP services, and treatment for contraceptive-related side effects.
Number of subjects: 2143
Study 35609202 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning intervention (FP)
Number of subjects: 2143
Study 33265966 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 151
Study 35122952 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 173
Study 35122952 — intervention group
Group type: COMPARATOR
Intervention: Individual and group supportive therapy
Number of subjects: 173
Study 33191061 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy flux density (H-ESWT) - 7 sessions (0.26 mJ/mm2)
Number of subjects: 94
Study 33191061 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy flux density (H-ESWT) - 3 sessions (0.26 mJ/mm2)
Number of subjects: 94
Study 33191061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy flux density (LESWT) - 7 sessions (<0.08 mJ/mm2)
Number of subjects: 94
Study 33191061 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group 1 (H-ESWT 7 sessions) and Group 2 (H-ESWT 3 sessions)
Number of subjects: 94
Study 33191061 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group 2 (H-ESWT 3 sessions) and Group 3 (LESWT 7 sessions)
Number of subjects: 94
Study 32771369 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based decision aid
Number of subjects: 253
Study 32771369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 253
Study 33924645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (150,000 IU) administered 24 hours before the run
Number of subjects: 35
Study 33924645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 32243043 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 929
Study 32243043 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec 100 U/mL (IDeg-100)
Number of subjects: 929
Study 33191598 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to pro-conspiracy articles
Number of subjects: 790
Study 33191598 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to anti-conspiracy articles
Number of subjects: 790
Study 33191598 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral articles)
Number of subjects: 790
Study 33191598 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to antidepressant conspiracy theories (Study 3)
Number of subjects: 790
Study 33191598 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis of gender differences (Study 2)
Number of subjects: 790
Study 36072634 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial artery embolization (BAE)
Number of subjects: 92
Study 36072634 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 92
Study 33245631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile virtual intervention, Sister, I will tell you!©, including reflective writing and mindfulness meditation for 4 weeks.
Number of subjects: 34
Study 33245631 — intervention group
Group type: COMPARATOR
Intervention: Audio-guided mindfulness meditation (control group).
Number of subjects: 34
Study 35975641 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 198
Study 35975641 — intervention group
Group type: COMPARATOR
Intervention: Originator Infliximab
Number of subjects: 198
Study 35118982 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback before RP
Number of subjects: 57
Study 35118982 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback after RP
Number of subjects: 57
Study 35118982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback)
Number of subjects: 57
Study 35466013 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose escalation
Number of subjects: 0
Study 35466013 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy optimisation
Number of subjects: 0
Study 34449080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation
Number of subjects: 33
Study 34449080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary supplementation)
Number of subjects: 33
Study 34757917 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 42
Study 34757917 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 42
Study 34757917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DCB and DES
Number of subjects: 42
Study 34627967 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity EMS (n=10)
Number of subjects: 27
Study 34627967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity EMS (n=9)
Number of subjects: 27
Study 34627967 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=8)
Number of subjects: 27
Study 32479786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous haloperidol dose escalation at 2 mg every 4 h
Number of subjects: 68
Study 32479786 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic rotation with chlorpromazine at 25 mg every 4 h
Number of subjects: 68
Study 32479786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined haloperidol at 1 mg and chlorpromazine at 12·5 mg every 4 h
Number of subjects: 68
Study 34562775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest health literacy profile (n = 86, 15.1%)
Number of subjects: 568
Study 34562775 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate health literacy profile (n = 338, 59.5%)
Number of subjects: 568
Study 34562775 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest health literacy profile (n = 144, 25.4%)
Number of subjects: 568
Study 34562775 — intervention group
Group type: COMPARATOR
Intervention: Control for demographic variables
Number of subjects: 568
Study 33037990 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m2
Number of subjects: 40
Study 33037990 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly carfilzomib plus dexamethasone (Kd) 20/27 mg/m2
Number of subjects: 40
Study 34626757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting Position (SP)
Number of subjects: 41
Study 34626757 — intervention group
Group type: COMPARATOR
Intervention: Prone Position (PP)
Number of subjects: 41
Study 32574117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus dexamethasone (BD)
Number of subjects: 92
Study 32574117 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib plus dexamethasone plus cyclophosphamide (C‐BD)
Number of subjects: 92
Study 35133671 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg orally once daily for 24 weeks
Number of subjects: 110
Study 35133671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 35133671 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 110
Study 33600460 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height
Number of subjects: 230
Study 33600460 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved drinking water source
Number of subjects: 230
Study 33600460 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated AGP
Number of subjects: 230
Study 33600460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (female vs. male)
Number of subjects: 230
Study 33600460 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RBP
Number of subjects: 230
Study 33600460 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 230
Study 35058272 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-fluidics system
Number of subjects: 110
Study 35058272 — intervention group
Group type: COMPARATOR
Intervention: Gravity-fluidics system
Number of subjects: 110
Study 32629112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (PO) antibiotic therapy
Number of subjects: 323
Study 32629112 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) antibiotic therapy
Number of subjects: 323
Study 32629112 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of antibiotic therapy
Number of subjects: 323
Study 35668441 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 92
Study 35668441 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 92
Study 35668441 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and Moxibustion
Number of subjects: 92
Study 33566838 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppelganger-based training
Number of subjects: 0
Study 33566838 — intervention group
Group type: COMPARATOR
Intervention: Avatar of the same gender
Number of subjects: 0
Study 34396468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereboost® (American ginseng extract)
Number of subjects: 61